NCT02395744已完成不适用
The Occlusion Perfusion Catheter for Optimal Delivery of Paclitaxel for the Prevention of Endovascular Restenosis - Below the Knee
Horizons International Peripheral Group8 个研究点 分布在 1 个国家目标入组 11 人开始时间: 2015年3月11日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 11
- 试验地点
- 8
- 主要终点
- Freedom from clinically driven target lesion revascularization (CD-TLR)
研究概览
简要总结
The purpose of the COPPER - B study is to assess the feasibility, safety, and initial efficacy of paclitaxel administration using the OPC for the prevention of restenosis in infrapopliteal de novo and restenotic lesions and occlusions using a novel catheter, the OPC.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •General Inclusion Criteria:
- •Willing and able to provide informed consent and comply with all study requirements;
- •Candidate for an infrapopliteal percutaneous intervention;
- •Must be ≥ 18 years of age;
- •Rutherford category 3-6;
- •Willing and able to tolerate dual anti-platelet therapy (DAPT) for a minimum of one (1) month;
- •Labwork within acceptable limits according to standard of care;
- •INR < 2.0 if on warfarin or not on warfarin;
- •Sheath size used for the interventional procedure 6F, 7F, or 8F.
排除标准
- •Life expectancy < one (1) year;
- •Planned amputation prior to procedure;
- •Pregnancy or nursing (a pregnancy test is required for all women of childbearing capabilities ≤ 7 days prior to the index procedure);
- •Previous intervention of the target vessel with a drug eluting balloon, or drug delivery catheter;
- •Acute limb ischemia;
- •Known allergy to paclitaxel;
- •Known hypersensitivity to other drugs manufactured in Cremophor® EL (polyoxyethylated castor oil; e.g. Drugs containing polyoxyethylated castor oil are drugs such as miconazole, cyclosporine injection, nelfinavir mesylate, saperconazole, tacrolimus, and xenaderm ointment);
- •Known allergy to anticoagulants;
- •Known TRUE acetylsalicylic acid (ASA) allergy;
- •Use of glycoprotein (GP) IIb/IIIa inhibitors during the procedure visit within 30 days prior to the index procedure;
- •Target lesion treated with a cryoplasty balloon at the time of the index procedure;
- •Current enrollment in another investigational device or drug study;
- •After obtaining informed consent, at any point up to introduction of the OPC, the investigator determines the study subject is not appropriate for the study;
- •Hemorrhagic stroke within three (3) months;
- •Renal failure or chronic kidney disease with GFR ≤30 ml/min or MDRD GFR ≤30 ml/min per 1.73 m2 (or serum creatinine ≥2.5 mg/L within 30 days of index procedure or patient is on dialysis);
- •Prior vascular surgery of the index limb.
- •Angiographic Inclusion Criteria
- •Reference vessel diameter (RVD) ≥ 2mm and ≤ 4mm;
- •Single or multiple lesions in the infrapopliteal arteries (AT, PT, peroneal);
- •If single lesion treatment, the minimum lesion length required is 2cm;
- •Lesion location must in the area from the origin of the trifurcation vessel to the ankle (top of the talus bone);
- •Minimum of one vessel run-off;
- •Pre-intervention percent DS ≥ 70%;
- •Target vessel reconstitutes at/above the ankle;
- •Infrapopliteal treatment prior to infrapopliteal OPC treatment resulting in ≤ 30% residual stenosis;
- •Infrapopliteal interventional treatment length is within the area of 1cm below the level of the knee joint to the malleolus, except in the case where an anomalous take-off of an infrapopliteal artery comes of at mid-knee joint.
- •Angiographic Exclusion Criteria
- •Flow limiting dissection requiring stent placement;
- •Post PTA residual stenosis > 30% as visualized by treating physician;
- •Perforation requiring a covered stent;
- •Lesion is above the trifurcation;
- •In-stent restenosis in target vessel;
- •Significant (≥ 50% DS) inflow lesion or occlusion left untreated in the ipsilateral Iliac, SFA, or popliteal artery proximal to the target lesion;
- •Lesions in the target vessel not treated with the OPC;
- •Visible thrombus in the target artery or proximal to the target artery.
结局指标
主要结局
Freedom from clinically driven target lesion revascularization (CD-TLR)
时间窗: 6 months
Freedom from major adverse events (MAEs)
时间窗: 6 months
次要结局
- Device success(Index Procedure)
- Improvement in Rutherford category(6 Months)
- Improvement in ABI(6 months)
- Freedom from Target Vessel Revascularization(6 Months)
- Improvement in wound healing(6 months)
- Device or procedure related serious adverse events (SAEs)(1 month)
- Treatment related anticipated adverse events (AEs)(1, 3, and 6 months)
- Treatment related serious adverse events (SAEs)(3 and 6 months)
研究者
研究点 (8)
Loading locations...
相似试验
已完成
不适用
The OPC for Optimal Delivery of Paclitaxel for the Prevention of Endovascular Restenosis - Above and Below the KneeCardiovascular DiseasePeripheral Arterial DiseasePeripheral Vascular DiseaseNCT02464501Horizons International Peripheral Group112
已完成
不适用
Connected Catheter (C2P) Study for Bladder ManagementUrinary RetentionNeurogenic BladderNCT03626324Spinal Singularity27
已完成
不适用
A Pilot Study Evaluating the Safety and Effectiveness of a New Pleural Catheter for the Medical Management of Symptomatic, Recurrent, Malignant Pleural EffusionsMalignant Pleural EffusionsNCT02227732C. R. Bard10
终止
不适用
Evaluation of the Safety and Clinical Performance of the Connected Catheter StudyUrinary RetentionChronicNCT05330598Spinal Singularity26
已完成
不适用
Randomized Clinical Trial on Transanal IrrigationLow Anterior Resection SyndromeNCT04586634Coloplast A/S32